Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Conditions
COVID-19, Healthy
Interventions
GLS-5310 (Group 1), GLS-5310 (Group 2), GLS-5310 (Group 3), GLS-5310 (Group 4)
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Rockville, Maryland • Lincoln, Nebraska
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GLS-5700 in Dengue Virus-Naïve Adults

NCT02809443
Conditions
Healthy
Interventions
GLS-5700
Biological
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Conditions
Pneumonitis, SARS-CoV Infection
Interventions
GLS-1027, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Ebola Vaccine
Interventions
INO-4201, INO-4202, INO-4212, INO-4212 + INO-9012, INO-4201 + INO-9012
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Missouri • Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

NCT04408183
Conditions
SARS-CoV 2, Infection
Interventions
GLS-1200, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Philadelphia, Pennsylvania • Conroe, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study of VGX-1027 in Healthy Subjects

NCT00760396
Conditions
Healthy
Interventions
VGX-1027
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Sinusitis Chronic
Interventions
GLS-1200, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy
Interventions
VGX-1027
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy
Interventions
GLS-5300
Biological
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland